1-5 of 5
Liang Xiu
Close
Sort by
Journal Articles

Patient-Reported Disease Burden in the Elderly Patients with Acute Myeloid Leukemia

Renee Pierson, MBA, Jianming He, PhD, Liang Xiu, PhD, Sepideh Nemat, MD PhD, Christina Loefgren, MD PhD, Xavier Thomas, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2182.
https://doi.org/10.1182/blood.V130.Suppl_1.2182.2182
Published: 2017
Journal Articles

Relationship between Complete Remission and Overall Survival in Acute Myeloid Leukemia: A Report from Daco-016 and Daco-017

Jianming He, PhD, Margaret T. Doyle, BSPharm, MSc, Liang Xiu, PhD, Sepideh Nemat, MD PhD, Christina Loefgren, MD PhD, Xavier Thomas, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2589.
https://doi.org/10.1182/blood.V130.Suppl_1.2589.2589
Published: 2017
Journal Articles

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma

Robert Z. Orlowski, MD, PhD, Arnon Nagler, MD, Pieter Sonneveld, MDPhD, Joan Bladé, MD PhD, Roman Hajek, Andrew Spencer, MD, Tadeusz Robak, MD, Anna Dmoszynska, Noemi Horvath, MB,ChB, FRACP, FRCPA, Ivan Spicka, Heather J. Sutherland, MD PhD FRCPC, Alexander Suvorov, MD, Liang Xiu, Trilok V. Parekh, PhD, Jesús San Miguel, MD
Journal: Blood
Blood (2014) 124 (21): 3448.
https://doi.org/10.1182/blood.V124.21.3448.3448
Published: 2014
Journal Articles

Assessment of Tumor Growth (g) and Regression (d) Rate Constants in Patients with Multiple Myeloma (MM) Shows That the Superiority of Bortezomib with Liposomal Doxorubicin (PLD+B) Over Bortezomib Alone (B) Is a Result of Reduced Growth of Refractory Tumor Cells and Not of Higher Regression Rates, and Provides An Earlier Efficacy Endpoint That Allows for Comparison Across Trials

Elisabet E. Manasanch, MD, Julia Wilkerson, BS, Liang Xiu, Sen Zhuang, MD, PhD, Susan Bates, MD, Wilfred Stein, PhD, Antonio T Fojo, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 5113.
https://doi.org/10.1182/blood.V118.21.5113.5113
Published: 2011
Journal Articles

The Combination of Pegylated Liposomal Doxorubicin and Bortezomib Significantly Improves Time to Progression of Patients with Relapsed/Refractory Multiple Myeloma Compared with Bortezomib Alone: Results from a Planned Interim Analysis of a Randomized Phase III Study.

Robert Z. Orlowski, MD, PhD, Sen H. Zhuang, MD, PhD, Trilok Parekh, PhD, Liang Xiu, PhD, Jean-Luc Harousseau, MD, the DOXIL-MMY-3001 Study Investigators
Journal: Blood
Blood (2006) 108 (11): 404.
https://doi.org/10.1182/blood.V108.11.404.404
Published: 2006